Pages that link to "Q34636847"
Jump to navigation
Jump to search
The following pages link to Concentrate safety and efficacy (Q34636847):
Displaying 10 items.
- Use of proteomics for validation of the isolation process of clotting factor IX from human plasma (Q33637509) (← links)
- Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry (Q33962436) (← links)
- Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates (Q34536476) (← links)
- Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy (Q36643868) (← links)
- Therapeutic plasma proteins – application of proteomics in process optimization, validation, and analysis of the final product (Q37872258) (← links)
- Five in one therapy for graded treatment of haemophilic arthritis (Q39186314) (← links)
- Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT. (Q45855060) (← links)
- Practice patterns in haemophilia A therapy -- global progress towards optimal care (Q45855105) (← links)
- Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A (Q45863724) (← links)
- Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. (Q45868033) (← links)